Diagnose und Therapie der Multiplen Sklerose

Die Multiple Sklerose ist die häufigste chronisch-entzündliche Erkrankung des zentralen Nervensystems in Europa. Gerade die Tatsache, dass vorwiegend jüngere Menschen betroffen sind, unterstreicht die besondere sozioökonomische Bedeutung der Krankheit. Eine frühzeitige Diagnosestellung ermöglicht die zeitnahe Einleitung einer wirksamen immunmodulierenden Therapie und somit eine langfristige erfolgreiche Behandlung der Multiplen Sklerose.

• Literatur

• 1 Kobelt G, Thompson A, Berg J. et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017; 23: 1123-1136
• 2 Orton SM, Herrera BM, Yee IM. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-936
• 3 Bjornevik K, Cortese M, Healy BC. et al. Longitudinal analysis re-veals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022; 375: 296-301
• 4 Ramagopalan SV, Dobson R, Meier UC. et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727-739
• 5 Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol 2019; 26: 27-40
• 6 Lublin FD, Reingold SC. National Multiple Sclerosis Society (USA) Advisory Committee of Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international sur-vey. Neurology 1996; 46: 907-11
• 7 Lublin FD, Reingold SC, Cohen JA. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-86
• 8 Hemmer B. Deutsche Gesellschaft für Neurologie. et al. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-SpektrumErkrankungen und MOG-IgG-assoziierten Erkrankungen. S2k-Leitlinie 2021. Leitlinien für Diagnostik und Therapie in der Neurologie; Accessed September 19, 2022 at: https://www.dgn.org/leitlinien
• 9 Thompson AJ, Banwel BL, Barkhof F. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162-73
• 10 Miller DH, Weinshenker BG, Filippi M. et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-74
• 11 Solomon AJ, Bourdette DN, Cross AH. The contemporary spectrum of multiple sclerosis misdiagnosis: a multi-center study. Neurology 2015; 87: 1393-99
• 12 Jarius S, Eichhorn P, Franciotta D. et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol 2017; 264: 453-66
• 13 Plantone D, De Angelis F, Doshi A. et al. Secondary progressive multiple sclerosis: definition and measurement. CNS Drugs 2016; 30: 517-26
• 14 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52
• 15 Grauer O, Offenhausser M, Schmidt J. et al. Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations. Nervenarzt 2001; 72: 577-89
• 16 Krankheitsbezogenes Kompetenznetz Multiple Sklerose e.V.. Qualitätshandbuch MS/NMOSD. Empfehlungen zur Therapie der Multiplen Sklerose/Neuro myelitis-optica-Spektrum Erkrankungen für Ärzte. 2021 Accessed September 19, 2022 at: https://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2021/12/KKN_2107_FINAL_medikamentenhandbuch-06.12.2021.pdf
• 17 Trebst C, Reising A, Kielstein JT. et al. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009; 28: 108-15
• 18 Ehler J, Koball S, Sauer M. et al. Response to therapeutic plasma exchange as a rescue treatment in clinically iso-lated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients. PLoS One 2015; 10: e0134583
• 19 Wiendl H, Gold R, Berger T. et al. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) . Nervenarzt 2021; 92: 773-801
• 20 Cree BA, Gourraud PA. University of California San Francisco MS-EPIC Team. et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80: 499-510
• 21 Ziemssen T, Derfuss T, de Stefano N. et al. Optimizing treatment success in multiple sclerosis. J Neurol 2016; 263: 1053-1065
• 22 Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Ocrelizumab. 2018 Accessed September 19, 2022 at: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/343/
• 23 Phé V, Schneider MP, Peyronnet B. et al. Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn 2018; 37: 67-82
• 24 Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300
• 25 Weinshenker BG, Bass B, Rice GPA. et al. The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 1989; 112: 133-46
• 26 Tintoré M, Rovira À, Río J. et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138: 1863-74
• 27 Bsteh G, Ehling R, Lutterotti A. et al. Long term clinical prognostic factors in relapsingremitting multiple sclerosis: insights from a 10-year observational study. PLoS One 2016; 11: e0158978
• 28 Cree BAC, Gourraud PA, Oksenberg JR. et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80: 499-510
• 29 Schwenkenbecher P, Wurster U, Konen FF. et al. Impact of the McDonald criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis. Front Neurol 2019; 10: 188